Colistin is the last resort for treatment of multidrug-resistant Acinetobacter baumannii.
Unfortunately, resistance to colistin has been reported all over the world. The highest …

Multidrug-resistant Acinetobacter baumannii has emerged as a significant clinical problem
worldwide and colistin is being used increasingly as “salvage” therapy. MICs of colistin …

Emerging resistance to colistin in clinical Acinetobacter baumannii isolates is of growing
concern. Since current treatment options for these strains are extremely limited, we …

At present, colistin is among the few antibiotics effective against Acinetobacter baumannii
clinical isolates. However, in the last few years, colistin-resistant A. baumannii strains have …

Background: Colistin is one of the few remaining options for carbapenem-resistant
Acinetobacter baumannii (A. baumannii); however, emergence of resistance from …

Background Colistin is being increasingly used for treatment of infections caused by
multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii. Methods …

Colistin is used as the “last resort” to treat infections caused by multidrug-resistant
Acinetobacter baumannii, which is at the top of the World Health Organization's list of the …

Multidrug-resistant Acinetobacter baumannii infection has presented a global medical
challenge. The antibiograms of paired colistin-susceptible and-resistant strains revealed …

Objectives The increased incidence of nosocomial infections by multidrug-resistant
organisms has motivated the re-introduction of colistin in combination with other …

Acinetobacter baumannii is recognized as a clinically significant pathogen causing a wide
spectrum of nosocomial infections. Colistin was considered a last-resort antibiotic for the …